AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16838826 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial dosage reduction by patients themselves just before tapering off
Number of subjects: 180
Study 16838826 — intervention group
Group type: EXPERIMENTAL
Intervention: Less severe benzodiazepine dependence (measured by Lack of Compliance subscale)
Number of subjects: 180
Study 16838826 — intervention group
Group type: EXPERIMENTAL
Intervention: No use of alcohol
Number of subjects: 180
Study 12782534 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-aluminum-hydroxide-simethicone suspension (MgAl)
Number of subjects: 10
Study 12782534 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 10697140 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of bismuth-based triple therapy (amoxicillin, metronidazole, bismuth subcitrate)
Number of subjects: 90
Study 10697140 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of bismuth-based triple therapy (amoxicillin, metronidazole, bismuth subcitrate)
Number of subjects: 90
Study 9351030 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg twice daily plus Amoxicillin 750 mg three times daily for 10 days
Number of subjects: 95
Study 9351030 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine prophylaxis 150 mg at night for 2 years
Number of subjects: 95
Study 8224263 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.300 mg administered orally) once
Number of subjects: 13
Study 8224263 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing factor (GH-RF) (1 micrograms/kg IV) repeated twice
Number of subjects: 13
Study 8224263 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 13
Study 8224263 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone-releasing factor
Number of subjects: 13
Study 3910523 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 100
Study 3910523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus Caved-S
Number of subjects: 100
Study 31604477 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt Swap intervention
Number of subjects: 40
Study 31604477 — intervention group
Group type: COMPARATOR
Intervention: Control information leaflet
Number of subjects: 40
Study 29860740 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed PCI (n=30)
Number of subjects: 96
Study 29860740 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (n=21)
Number of subjects: 96
Study 26992483 — intervention group
Group type: EXPERIMENTAL
Intervention: Video segment of peers consuming bell pepper (vegetable condition)
Number of subjects: 42
Study 26992483 — intervention group
Group type: COMPARATOR
Intervention: Nonfood video segment or no video (control condition)
Number of subjects: 42
Study 26992483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable DVD condition
Number of subjects: 42
Study 25355977 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mail
Number of subjects: 0
Study 25355977 — intervention group
Group type: EXPERIMENTAL
Intervention: fax
Number of subjects: 0
Study 25355977 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 0
Study 25355977 — intervention group
Group type: COMPARATOR
Intervention: no-message control group
Number of subjects: 0
Study 22207322 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron infusion during HD session
Number of subjects: 10
Study 22207322 — intervention group
Group type: COMPARATOR
Intervention: Iron preparations (iron gluconate, iron sucrose, iron dextran, ferric carboxymaltose)
Number of subjects: 10
Study 22207322 — intervention group
Group type: COMPARATOR
Intervention: Culture of mononuclear cells with iron preparations
Number of subjects: 10
Study 22207322 — intervention group
Group type: COMPARATOR
Intervention: Generic formulation of iron sucrose
Number of subjects: 10
Study 20598032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg/6 h)
Number of subjects: 220
Study 20598032 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg/6 h)
Number of subjects: 220
Study 20598032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 220
Study 20598032 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 220
Study 18076346 — intervention group
Group type: EXPERIMENTAL
Intervention: sapropterin 10 mg/kg/day (n = 41)
Number of subjects: 485
Study 18076346 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 47)
Number of subjects: 485
Study 16195288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine
Number of subjects: 2485
Study 16195288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2485
Study 11772188 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-intervention group (home-safety visit by a community health worker)
Number of subjects: 0
Study 11772188 — intervention group
Group type: COMPARATOR
Intervention: Standard-intervention group (safety counseling and referral to the children's safety center)
Number of subjects: 0
Study 11772188 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's safety center visitors
Number of subjects: 0
Study 9688015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose albuterol (two 5.0 mg doses administered during 40 minutes)
Number of subjects: 160
Study 9688015 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose albuterol (three 2.5 mg doses every 20 minutes)
Number of subjects: 160
Study 9688015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose albuterol
Number of subjects: 160
Study 7867110 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 60
Study 7867110 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 7867110 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone/Propofol mixture
Number of subjects: 60
Study 2530123 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage multivitamin and mineral supplements
Number of subjects: 15
Study 2530123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 236108 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam, 0.4 mg
Number of subjects: 25
Study 236108 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam, 0.8 mg
Number of subjects: 25
Study 236108 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam, 15 mg
Number of subjects: 25
Study 236108 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam, 30 mg
Number of subjects: 25
Study 236108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 236108 — intervention group
Group type: EXPERIMENTAL
Intervention: All active medications
Number of subjects: 25
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health campaign
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-administered home-based testing
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of HIV self-test kits at local pharmacies
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Two community-based testing services provided concurrently
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to antiretroviral therapy (ART)
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disease testing availability
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: US$0.85 incentive
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of having HIV
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group comparison
Number of subjects: 203
Study 31981135 — intervention group
Group type: EXPERIMENTAL
Intervention: Income comparison
Number of subjects: 203
Study 31314954 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ12048189
Number of subjects: 25
Study 31314954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28614364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-peritoneal bolus of 30ml bupivacaine 0.25%
Number of subjects: 20
Study 28614364 — intervention group
Group type: COMPARATOR
Intervention: Epidural bolus of 10ml bupivacaine 0.25%
Number of subjects: 20
Study 28614364 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration (CWI)
Number of subjects: 20
Study 26525144 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy for problem sexual behaviour (MST-PSB)
Number of subjects: 80
Study 26525144 — intervention group
Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 80
Study 23883510 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual haptic simulator for fixation of an ulna
Number of subjects: 22
Study 23883510 — intervention group
Group type: COMPARATOR
Intervention: Sawbones
Number of subjects: 22
Study 21721591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (OTG) 1 g containing oxybutynin chloride 10%, applied once daily to the abdomen, upper arm/shoulder, or thigh.
Number of subjects: 12
Study 21721591 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-application showering (1-6 hours after dosing) and sunscreen application (30 minutes before or after OTG application).
Number of subjects: 12
Study 21721591 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (transference study) between treated and untreated participants.
Number of subjects: 12
Study 20053323 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept treatment
Number of subjects: 426
Study 16954128 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude manipulation (HVLA)
Number of subjects: 19
Study 16954128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated performance-enhancement stickers)
Number of subjects: 19
Study 15138107 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg daily
Number of subjects: 429
Study 15138107 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 429
Study 10977011 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 41
Study 10977011 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 41
Study 10977011 — intervention group
Group type: COMPARATOR
Intervention: Both CSII and MDI
Number of subjects: 41
Study 9580803 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous apomorphine infusion
Number of subjects: 10
Study 9580803 — intervention group
Group type: COMPARATOR
Intervention: Patch testing to apomorphine and its preservative
Number of subjects: 10
Study 9580803 — intervention group
Group type: COMPARATOR
Intervention: Serum IgE levels measurement
Number of subjects: 10
Study 8160978 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 70
Study 8160978 — intervention group
Group type: COMPARATOR
Intervention: Propofol plus nitrous oxide
Number of subjects: 70
Study 3041826 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl tablets
Number of subjects: 12
Study 3041826 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur tablets
Number of subjects: 12
Study 3041826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3041826 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl tablets and Theo-Dur tablets
Number of subjects: 12
Study 3041826 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline phases
Number of subjects: 12
Study 3041826 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 12
Study 3041826 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl tablet phase
Number of subjects: 12
Study 31861049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical composition containing creatine, D-ribose, vitamin B1, and vitamin B6
Number of subjects: 53
Study 31861049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 29903044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 30
Study 29903044 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 30
Study 27013546 — intervention group
Group type: EXPERIMENTAL
Intervention: Entry to a $500 prize draw
Number of subjects: 0
Study 27013546 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 donation to charity
Number of subjects: 0
Study 27013546 — intervention group
Group type: COMPARATOR
Intervention: No incentive (control)
Number of subjects: 0
Study 23736378 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-2 appliance treatment for 1.7 years
Number of subjects: 34
Study 23736378 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated class II subjects)
Number of subjects: 34
Study 23736378 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-2 appliance treatment
Number of subjects: 34
Study 22554048 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement (ERL)
Number of subjects: 19
Study 22554048 — intervention group
Group type: COMPARATOR
Intervention: Manual scaling and root planning (SRP)
Number of subjects: 19
Study 22554048 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ERL and SRP
Number of subjects: 19
Study 19346292 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0
Study 17244778 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 30
Study 17244778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17244778 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 30
Study 15082468 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day for 6 weeks
Number of subjects: 0
Study 15082468 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg four times a day for 6 weeks
Number of subjects: 0
Study 15082468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15082468 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for Celecoxib
Number of subjects: 0
Study 15082468 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for Acetaminophen
Number of subjects: 0
Study 12149301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus 5-FU (600 mg/m(2)/wk) weekly for 3 weeks of every 4 weeks
Number of subjects: 322
Study 12149301 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1,000 mg/m(2)/wk) weekly for 3 weeks of every 4 weeks
Number of subjects: 322
Study 10460103 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg under fasting conditions
Number of subjects: 14
Study 10460103 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg with aluminum-magnesium antacid
Number of subjects: 14
Study 10460103 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg with a high-fat meal
Number of subjects: 14
Study 8570532 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem sustained release pellets (coated with 0.6% ethylcellulose/dibutyl sebacate)
Number of subjects: 0
Study 8570532 — intervention group
Group type: COMPARATOR
Intervention: Cardizem tablets
Number of subjects: 0
Study 2082314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 227
Study 2082314 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 227
Study 519877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 40
Study 519877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7130407 — intervention group
Group type: EXPERIMENTAL
Intervention: Group condition (parent training plus group behavior therapy)
Number of subjects: 15
Study 7130407 — intervention group
Group type: COMPARATOR
Intervention: Individual condition (individual family behavior therapy)
Number of subjects: 15
Study 30863856 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte apheresis (Group A)
Number of subjects: 24
Study 30863856 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (Group P)
Number of subjects: 24
Study 28376460 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 62
Study 28376460 — intervention group
Group type: COMPARATOR
Intervention: Print intervention
Number of subjects: 62
Study 26044148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone suppositories (400 mg daily starting at 20‐24 weeks of gestation)
Number of subjects: 250
Study 26044148 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 250
Study 24531792 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketamine plus 4% amitriptyline (KA) cream
Number of subjects: 462
Study 24531792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 23050461 — intervention group
Group type: EXPERIMENTAL
Intervention: LaSota vaccine (virus titers ranging from 10(2) to 10(8) EID50 in 10-fold increments)
Number of subjects: 0
Study 23050461 — intervention group
Group type: EXPERIMENTAL
Intervention: LaSota vaccine (adequate titer)
Number of subjects: 0
Study 19572933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg pre-operatively (G2)
Number of subjects: 126
Study 19572933 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-operatively (G1)
Number of subjects: 126
Study 19572933 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo post-operatively (G3)
Number of subjects: 126
Study 19572933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg post-operatively (G3)
Number of subjects: 126
Study 19572933 — intervention group
Group type: COMPARATOR
Intervention: Placebo post-operatively (G1)
Number of subjects: 126
Study 18097856 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 291
Study 18097856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 18097856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exacerbation rate during the first 14‐day interval
Number of subjects: 291
Study 18097856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exacerbation rate during the second 14‐day interval
Number of subjects: 291
Study 15089838 — intervention group
Group type: EXPERIMENTAL
Intervention: Veda-scope
Number of subjects: 250
Study 15089838 — intervention group
Group type: COMPARATOR
Intervention: bivalve speculum
Number of subjects: 250
Study 12059987 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 116
Study 12059987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 116
Study 10094637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg in 2 ml of normal saline)
Number of subjects: 186
Study 10094637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 ml of normal saline)
Number of subjects: 186
Study 10094637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 10094637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 186
Study 8789481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100
Study 8789481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1981137 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 86466 200 micrograms kg‐1
Number of subjects: 8
Study 94637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (5 mg q.i.d.)
Number of subjects: 16
Study 94637 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (500 mg q.i.d.)
Number of subjects: 16
Study 94637 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg twice daily)
Number of subjects: 16
Study 94637 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (substituted for prazosin or methyldopa)
Number of subjects: 16
Study 31899371 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity monitor (Fitbit wearable activity monitor and mobile app with goal setting and physical activity prescription)
Number of subjects: 312
Study 31899371 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity monitor + text messaging
Number of subjects: 312
Study 31899371 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal calls
Number of subjects: 312
Study 31899371 — intervention group
Group type: EXPERIMENTAL
Intervention: Group meetings
Number of subjects: 312
Study 28457189 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive remediation therapy (CCRT)
Number of subjects: 66
Study 28457189 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 66
Study 28753032 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligner
Number of subjects: 41
Study 28753032 — intervention group
Group type: COMPARATOR
Intervention: Traditional fixed appliance
Number of subjects: 41
Study 25956341 — intervention group
Group type: EXPERIMENTAL
Intervention: Valnemulin hydrochloride premix at 20 ppm
Number of subjects: 0
Study 25956341 — intervention group
Group type: EXPERIMENTAL
Intervention: Valnemulin hydrochloride premix at 35 ppm
Number of subjects: 0
Study 25956341 — intervention group
Group type: COMPARATOR
Intervention: Control (non-medicated)
Number of subjects: 0
Study 25956341 — intervention group
Group type: EXPERIMENTAL
Intervention: Valnemulin hydrochloride (20 ppm and 35 ppm)
Number of subjects: 0
Study 25956341 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 0
Study 23388155 — intervention group
Group type: COMPARATOR
Intervention: MD-GAL (0.9 g MD/kg body mass (BM) per h and 0.3 g GAL/kg BM per h)
Number of subjects: 7
Study 23388155 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-GAL-PRO+AA (0.5 g MD/kg BM per h, 0.3 g GAL/kg BM per h, 0.4 g whey PRO hydrolysate plus l-leucine and l-phenylalanine/kg BM per h)
Number of subjects: 7
Study 21846036 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-therapy
Number of subjects: 115
Study 21846036 — intervention group
Group type: COMPARATOR
Intervention: Control (no vacuum-therapy)
Number of subjects: 115
Study 18772180 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus-eluting stent (SES)
Number of subjects: 79